Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm ...

UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...

A New Jersey-based biotech is looking to become the main character in the age-related macular degeneration field. | A New Jersey-based biotech is looking to become the main character in the ...

Building upon its already impressive obesity drug portfolio, Novo Nordisk A/S has licensed a triple agonist of the receptors for GLP-1, GIP and glucagon from United Biotechnology Co. Ltd. China-based ...

The Australian biotech could potentially be on the hook for more than $1bn after sozinibercept failed to show impact over ...

Australia-based Opthea, a biopharma developing therapies for progressive retinal diseases, has announced results from its ...

Opthea's sozinibercept and Unity's UBX1325 fail to match Regeneron's Eylea in separate eye disease trials; Opthea faces ...

The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients with diabetic macular edema (DME) who had poor ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...